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Abstract
Background:  CD4+CD25+ regulatory T cells play an essential role in maintaining immune
homeostasis and preventing autoimmunity. Therefore, defects in Treg development, maintenance
or function have been associated with several human autoimmune diseases including Systemic
Lupus Erythematosus (SLE), a systemic autoimmune disease characterized by loss of tolerance to
nuclear components and significantly more frequent in females.
Results: To investigate the involvement of Treg in SLE pathogenesis, we determined the frequency
of CD4+CD25+CD45RO+ T cells, which encompass the majority of Treg activity, in the PBMC of
148 SLE patients (76 patients were part of 54 families), 166 relatives and 117 controls. SLE patients
and their relatives were recruited in several Portuguese hospitals and through the Portuguese
Lupus Association. Control individuals were blood donors recruited from several regional blood
donor centers. Treg frequency was significantly lower in SLE patients than healthy controls (z = -
6.161, P < 0.00001) and intermediate in the relatives' group. Remarkably, this T cell subset was also
lower in females, most strikingly in the control population (z = 4.121, P < 0.001). We further
ascertained that the decreased frequency of Treg in SLE patients resulted from the specific
reduction of bona fide FOXP3+CD4+CD25+ Treg. Treg frequency was negatively correlated with
SLE activity index (SLEDAI) and titers of serum anti-dsDNA antibodies. Both Treg frequency and
disease activity were modulated by IVIg treatment in a documented SLE case. The segregation of
Treg frequency within the SLE families was indicative of a genetic trait. Candidate gene analysis
revealed that specific variants of CTLA4 and TGF were associated with the decreased frequency of
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Treg in PBMC, while FOXP3 gene variants were associated with affection status, but not with Treg
frequency.
Conclusion:  SLE patients have impaired Treg production or maintenance, a trait strongly
associated with SLE disease activity and autoantibody titers, and possibly resulting from the inability
to convert FOXP3+CD25- into FOXP3+CD25+ T cells. Treg frequency is highly heritable within SLE
families, with specific variants of the CTLA4 and TGF genes contributing to this trait, while FOXP3
contributes to SLE through mechanisms not involving a modulation of Treg frequency. These
findings establish that the genetic components in SLE pathogenesis include genes related to Treg
generation or maintenance.
Background
Immunological tolerance is a key feature of the immune
system that allows the organism to discriminate self from
nonself, providing defense against foreign pathogens
while preventing autoimmunity. This ability of the
immune system is controlled by mechanisms of central
and peripheral tolerance. Central tolerance involves dele-
tion of self-reactive T cells in the thymus at an early stage
of development [1]. However, this mechanism alone is
not sufficient for preventing autoimmunity, as autoreac-
tive T cells are also detected in healthy individuals [2]. A
second mechanism involves the thymic selection of a
population of regulatory T cells (Treg), which dominantly
prevents both the activation and the effector function of
autoreactive T cells that have eluded other mechanisms of
tolerance [3]. The depletion or inactivation of Treg leads
to the development of a wide range of autoimmune and
inflammatory manifestations such as gastritis, oophoritis,
orchitis, thyroiditis, inflammatory bowel disease and
spontaneous autoimmune diabetes, in animal models
[4]. In addition, reduced numbers of this cellular subset
have been found in murine models of SLE [5].
T cells expressing the high affinity T Cell Receptor (TCR)
for antigens expressed on the thymic epithelium [6] are
selected in the thymus, originating Treg cells able to sup-
press both proliferation and cytokine production by effec-
tor cells in a cell-contact dependent manner. The
mechanisms involved in Treg generation, maintenance or
function have not been fully clarified. For instance, while
CTLA-4-/- mice develop an early lymphoproliferative dis-
ease [7] and CTLA4 gene expression in the thymus appears
instrumental for T cell selection [8], some regulatory T
cells can be generated in the absence of CTLA-4 [9]. Given
its wide ranged immuno-suppressor activity, TGF- was
first thought to be a mediator of Treg activity [10], but is
nowadays known to play a major role in Treg homeostasis
by promoting their proliferation [11].
In humans, Treg are highly enriched in the cellular subset
expressing CD4, the  chain of the IL-2 receptor (CD25)
and the memory marker CD45RO [12]. Low numbers or
functional defects in CD4+CD25+ T cells have been found
in patients with SLE [13,14], immune-mediated diabetes
[15], and multiple sclerosis [16]. Natural CD4+CD25+
Treg express the transcription factor FOXP3, which con-
trols their development and function [17]. Functional
defects in the FOXP3 gene lead to the absence of Treg pro-
duction and to Immunodysregulation, Polyendocrinopa-
thy and Enteropathy, X-linked Syndrome (IPEX) [18]. The
control of immune cell numbers and effector functions in
response to lymphopenia, infection and autoimmune
reactivity are also under the strict control of Treg [19].
SLE is a chronic systemic autoimmune disease with
unknown etiology, and thought to result from the inter-
play between genetic and environmental factors [20].
Multiple immune system defects have been described in
patients with this condition, including B cell hyperactivity
and increased antinuclear autoantibody production,
defects in T cell activation and aberrant cytokine produc-
tion [21,22]. To establish the involvement of Treg in SLE
pathogenesis, we compared the frequency of
CD4+CD25+CD45RO+ T cells in SLE patients and controls
and correlated it with disease activity and antinuclear
autoantibody production. We also analyzed the frequency
of CD4+FOXP3+ cells in a subset of patients and investi-
gated Treg frequency variation with disease activity, sever-
ity and development and remission of symptoms in two
SLE cases. Further, we analyzed the segregation of
CD4+CD25+CD45RO+ frequency in SLE-affected families
and tested the candidate genes CTLA4, TGF, FOXP3, IL2
and CD25 for association with Treg frequency distribution
and with SLE.
Methods
Population sample
SLE patients and their relatives were recruited in several
hospitals throughout Portugal in collaboration with the
Portuguese Lupus Association. A total of 148 SLE patients
(136 females and 12 males) were enrolled in the present
study. 76 of the SLE patients were part of 54 families, from
which 166 relatives (98 females and 68 males) were also
included in the study. All patients met the revised 1997
American College of Rheumatology criteria for SLE [23],
independently of their disease activity at recruitment. TheBMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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SLE Disease Activity Index (SLEDAI) [24] was assessed for
each patient at the time of collection (SLEDAI range: 0–
41). Irreversible damage caused by the disease was calcu-
lated using the Systemic Lupus Erythematosus Interna-
tional Collaborating Clinics (SLICC) damage index.
Information on medication from each patient was col-
lected at recruitment. Patients and their relatives com-
pleted a 10 question screening questionnaire [25], used
here as an indication of autoimmune disease manifesta-
tions in each individual (Table 1). Control individuals (N
= 117, 58 females and 59 males) were blood donors
recruited from several regional blood centers. The popula-
tion sample characteristics and the numbers used in each
of the subsequent analyses are described in Additional file
1. Approval for this study was obtained from the Portu-
guese Ethics Committee for Life Sciences Research, and
collection of all biological samples was performed after
written informed consent from all participating individu-
als.
Cell surface staining and flow cytometry
PBMC were isolated using Vacutainer CPT™ tubes (Becton
Dickinson). For the CD4CD25CD45RO staining 1 × 106
cells were fixed in 2% PFA, washed twice in PBS 2% FCS
and subsequently incubated for 20 min at 4°C with the
optimal dilution of each conjugated anti-human mAb
(CD4-FITC, CD25-Cy-chrome, CD31-PE and CD45RO-
APC, Becton Dickinson). Cells were washed again and flu-
orescence intensity staining was analyzed using a FACS-
can flow cytometer (FACScalibur™ and CellQuest™
software, Becton Dickinson). CD4+CD25+ T cells were
defined, for all the individuals, as the population of CD4
positive T cells whose CD25 expression exceeded the level
of CD25 positivity seen in the CD4 negative T cells. The
CD4-FITC, CD25-APC, FOXP3-PE staining was per-
formed according to eBioscience manufacture protocol.
Anti-dsDNA autoantibody measurement by quantitative 
ELISA
Reacti-Bind™ EIA plates (Pierce) were coated overnight at
4°C with 1 mg/mL purified dsDNA (Sigma-Aldrich). The
plates were blocked with a solution of 1% gelatin for 5 h
at 4°C and incubated overnight at 4°C with test plasma
(in triplicates) at a total protein concentration was 0.5
mg/mL. Plates were then incubated overnight at 4°C with
50  L of alkaline phosphatase-conjugated anti-human
IgG (Sigma-Aldrich) and bound IgG was revealed using 1
mg/mL  p-nitrophenyl phosphate (Sigma-Aldrich).
Absorbance at 405 nm was measured in an ELISA plate
reader (BioRad). Quantification of each reactivity was
obtained by fitting ODs to a standard curve present in
duplicates on each plate, and consisting of 12 serial dilu-
tions of respective positive control sera. In the readout,
one unit was defined as the equivalent of the highest con-
centration used for the respective positive control serum,
which was previously chosen to be below the saturation
level. Fractions of one unit were consequently defined by
the dilution factor of this standard, at which it yielded an
OD equivalent to that obtained for a respective sample
[26].
Genotyping
Genomic DNA was isolated from PBMC by standard
methods. The polymorphic markers tested were selected
for their putative role in gene expression or function.
Within the CTLA4 gene, we genotyped a functional SNP
involving a missense A>G transition at +49 exon 1
(rs231775) and a 3'UTR microsatelite marker proposed to
influence mRNA stability and turnover [27]. In the TGF
gene, we genotyped a C>T transition in the promoter
(rs1800469) and a G>C SNP in exon 1 (rs1800471), both
known to be associated with the serum concentration of
TGF- [28,29]. Within the FOXP3 gene two microsatelite
markers were genotyped (one in intron 0, which has been
described as having a promoter/enhancer function and
other in intron 5) and a -1128 G>A SNP (rs12843496)
[30]. The IL2 gene, -384 G<T (rs2069762) and +114 G>T
Table 1: SLE survey questionnaire and percentage of patients and relatives that gave a positive answer to each question.
SLE survey questionnaire Positive answers
% of Patients % of Relatives
1. Have you ever had painful swollen joints for more than three months? 65.0 13.6
2. Do your fingers ever change color, become numb or uncomfortable in the cold? 63.3 26.4
3. Have you ever had mouth ulcers for more than two weeks? 40.0 18.6
4. Have you ever been told that you have low blood counts (anemia, low white cell count or low platelet count)? 71.7 15.0
5. Have you ever had an obvious or prominent rash on your cheeks for more than a month? 71.7 9.3
6. Do you develop a distinct rash in the sun (not just sunburn)? 66.7 10.0
7. Has it ever been painful to take a deep breath for more than just a few days (pleurisy)? 33.3 4.3
8. Have you ever been told that you have protein in the urine? 26.7 0.0
9. Do you find a lot of hair on your pillow on waking? 43.0 10.7
10.Have you ever had a seizure, convulsion or fit? 3.0 0.7BMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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(rs3087209) in the promoter and in exon 1, respectively,
were genotyped as previously described [30,31]. Within
the  CD25  gene, we genotyped a (CA)n repeat 10 kb
upstream of the gene (D10S189) and two SNPs,
rs2274037 (a A>G transition in exon 4) and rs1570538 (a
C>T transition in the 3'UTR region of CD25) as previously
described [32]. The D10S189 microsatelite marker was
genotyped using the Applied Biosystems fluorescence
based automated sequencer. Semi-automated fragment
sizing was performed using GENESCAN® 3.1.
mRNA isolation and quantification
Total RNA was isolated from 5 × 106 PBMC using the RNe-
asy Mini Kit (QIAGEN). The first strand cDNA was gener-
ated by reverse transcription with oligo dT primer
(Invitrogen). The CTLA-4, TGF-, FOXP3, IL-2 and CD25
mRNA levels were quantified with the LightCycler (Roche
Molecular Biochemicals) in 33 patients and 24 controls,
which were representative of the total population sample.
50 ng of first-stranded cDNA were amplified and real-time
fluorimetric intensity of SYBR green I was monitored. RT-
PCR reactions consisted in an initial denaturation step at
95°C for 10 minutes followed by 45 cycles of denatura-
tion at 95°C for 15 seconds, 56°C for 5 seconds and 72°C
for 23 seconds. The individual samples were standardized
by the amount of HPRT RNA. This RT-PCR reaction con-
sisted on an initial denaturation step at 95°C for 10 min-
utes followed by 45 cycles of denaturation at 95°C for 15
seconds, 60°C for 5 seconds and 72°C for 23 seconds.
Additionally, CTLA-4 and CD25 mRNA expression levels
were normalized by the proportion of CD4+ cells, given
that these molecules are mainly expressed by CD4+ T cells.
Statistical analysis
Nonparametric analysis of variance was performed using
the Mann-Whitney U and Kruskal-Wallis tests to compare
the distributions of T cell frequencies in patients and con-
trols. Results were considered significant at the 0.05 level.
Heritability estimation was performed by the SOLAR soft-
ware [33]. In this test the likelihood of the sporadic model
of no inheritance is compared with the likelihood of a
polygenic model of inheritance. The sporadic model con-
stitutes our null hypothesis in which it is assumed that
there is not a genetic component underlying the frequen-
cies of Treg cells. The polygenic model constitutes our test-
ing hypothesis, where the quantitative trait is considered
to be determined by a large number of genetic loci acting
independently and/or additively. The models are then
compared to find the hypothesis that is better supported
by the data. Hardy-Weinberg equilibrium (HWE) was
analyzed by the HWE exact test. Linkage disequilibrium
(LD) between two polymorphic markers was quantified as
D' using the HAPLOXT program implemented in the
GOLD software [34].
Results
Lower frequency of CD4+CD25+ and 
CD4+CD25+CD45RO+ cells in SLE patients
The previous observation that a CD4+CD25+ T cell sub-
population expressing the CD45RO activation marker
exhibits 75% higher suppressive activity [35] suggests that
the majority of Treg activity is restricted to CD45RO+ cells.
We therefore evaluated the frequency of both CD4+CD25+
and CD4+CD25+CD45RO+  T cell populations in total
lymphocyte PMBC samples of SLE patients, their relatives
and healthy controls and expressed it as a percentage of
total CD4+  cells (Figure 1A). CD4+CD25+  and
CD4+CD25+CD45RO+  T cell frequencies were signifi-
cantly decreased in patients compared to controls (Mann-
Whitney U test, z = -6.339, P < 0.00001 and z = -6.161, P
< 0.00001, respectively). CD4+CD25+  and
CD4+CD25+CD45RO+ T cell distribution in relatives was
intermediate between that of patients and controls (Figure
1B). As the frequency distributions of either cell popula-
tion were identical, the results obtained for the
CD4+CD25+CD45RO+ cell subset was considered for the
remaining of this study.
SLE affects primarily women and consequently only
about 10% of our patients are male, while our control
population is balanced in terms of gender. We therefore
tested whether this gender bias was not a confounding
factor in our interpretation. CD4+CD25+CD45RO+ T cell
frequency was significantly lower in healthy females than
in males (Mann-Whitney U test: z = 4.121, P < 0.001). The
CD4+CD25+CD45RO+ T cell frequency was also lower in
females than in males in the patient and relative groups,
although the difference did not reach statistical signifi-
cance (Figure 1C). Separate analysis within each gender
group shows that the CD4+CD25+CD45RO+ T cell fre-
quency is always significantly lower in patients (Mann-
Whitney U test, Males: z = -2.504, P = 0.012; females: z =
-3.864, P < 0.001).
CD25 is a marker for both Treg and activated cells. To rule
out the possibility that this T cell population is mainly
constituted by activated cells we measured the frequency
of the CD4+CD45RO+ T cells, since CD45RO expression is
associated with early activation events. No difference was
found in the frequency of CD4+CD45RO+ cells between
patients and controls (Mann-Whitney U test: z = -1.724, P
= 0.089), indicating that the CD25+  population was
largely a regulatory population.
To exclude a global thymic output defect, we evaluated the
percentage of recent thymic emigrants (RTE) inside the
CD4+ population using the phenotypic markers CD45RO-
CD31+ [36]. As expected, CD45RO-CD31+ cell frequency
decreased with age, but there were no differences between
patients and controls in absolute frequency or in theBMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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kinetics of decay (Figure 2A). Moreover, the frequency of
RTE did not correlate with the percentages of
CD4+CD25+CD45RO+ cells ( = 0.10, P = 0.094). How-
ever, the CD31+ cells inside CD4+CD25+ cells decreased
faster with age in patients than in controls (Figure 2B),
suggesting a defect specifically in thymic Treg cell produc-
tion in SLE patients. No significant difference was found
in the frequency of CD4+CD45RO-CD31+ or CD31+ cells
inside CD4+CD25+ between males and females (data not
shown).
SLE patients display higher frequency of CD4+FOXP3+ 
cells which are mainly CD25-
Given the major involvement of FOXP3 in the differenti-
ation and function of Treg, we analyzed the frequency of
FOXP3+ cells in a subset of 19 patients and 10 healthy
individuals. While the frequency of FOXP3+  cells in
CD4+PBMC was not significantly different between
patients and controls (Figure 3A), the frequency of CD25+
in the CD4+FOXP3+ cell subset was significantly reduced
Regulatory T cell frequency is lower in PBMC of SLE patients  than in controls (A) Lymphocytes gated according to forward  and side scatter (FSC/SSC) from PMBC were screened by  flow cytometry for the presence of CD4+CD25+ and  CD4+CD25+CD45+ T cells Figure 1
Regulatory T cell frequency is lower in PBMC of SLE 
patients than in controls (A) Lymphocytes gated 
according to forward and side scatter (FSC/SSC) 
from PMBC were screened by flow cytometry for the 
presence of CD4+CD25+ and CD4+CD25+CD45+ T 
cells. The FACS panel representing CD4+CD25+CD45RO+ 
PBMC is gated on CD4+ cells. Representative FACS stainings 
from an SLE patient and a healthy individual are shown, (B) 
box plot representing the frequency of CD4+CD25+ and 
CD4+CD25+CD45RO+ PBMC in patients (n = 76), relatives 
(n = 156) and controls (n = 193), showing that SLE patients 
have a significantly lower Treg frequency than healthy individ-
uals and (C) Relative distribution of CD4+CD25+CD45+ T 
cell frequency in CD4+ T cells between male and female 
patients, relatives and controls, showing that females have a 
significantly lower frequency of CD4+CD25+CD45+ T cell 
frequency than males.
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in patients when compared to healthy controls (Mann-
Whitney U test, z = 2.457, P = 0.014) (Figure 3B). In con-
trast, FOXP3-CD25+  activated cells were significantly
increased in SLE patients (Mann-Whitney U test, z  = -
2.377, P = 0.017) (Figure 3C). This diminished expression
of CD25 in patients' FOXP3+ cells indicates that the over-
all reduction in CD4+CD25+ cells in SLE patients likely
results specifically from a defect in the ability to convert
FOXP3+CD25- into FOXP3+CD25+ cells.
CD4+CD25+CD45RO+ T cell frequency is negatively 
correlated with SLE-associated phenotypes
Autoantibody production against dsDNA is a hallmark of
SLE. We therefore analyzed the plasma immunoreactivity
profiles against dsDNA from SLE patients, relatives and
healthy individuals. Overall, there is a negative correla-
tion between Treg frequency and anti-dsDNA in the total
population ( = -0.19, P = 0.0026) (Figure 4A), reinforc-
ing the notion that perturbations in the system that main-
tains immunologic unresponsiveness to self-constituents
lead to the loss of peripheral tolerance and to SLE. This
negative correlation between anti-dsDNA autoantibodies
and the frequency of CD4+CD25+CD45RO+ T cells was
also found in our patient ( = -0.37, P = 0.005) and con-
trol groups ( = -0.30, P = 0.022) (Figure 4A). Surpris-
ingly, there is a positive correlation between the frequency
of CD4+CD25+CD45RO+ T cells and anti-dsDNA antibod-
ies in the relatives' group ( = 0.29, P = 0.0004) (Figure
4A). No difference was found between males and females.
The CD4+CD25+CD45RO+ T cell frequency was inversely
correlated with disease activity measured by the SLEDAI
Relative distribution of (A) FOXP3+ cells in total CD4+  PBMC (B) CD25+ cells in total CD4+FOXP3+PBMC and (C)  CD25+ cells in total CD4+FOXP3- PBMC between patients (n  = 19) and controls (n = 10) Figure 3
Relative distribution of (A) FOXP3+ cells in total 
CD4+ PBMC (B) CD25+ cells in total 
CD4+FOXP3+PBMC and (C) CD25+ cells in total 
CD4+FOXP3- PBMC between patients (n = 19) and 
controls (n = 10).
(A) Negative correlation between CD4+CD25+CD45RO+ T  cell frequency and anti-DNA antibody titers in our popula- tion sample and correlations between  CD4+CD25+CD45RO+ T cell frequency and anti-DNA anti- body titers in patients relatives and controls (B) Negative  correlation between the percentage of CD25+CD45RO+ in  total CD4+ PBMC cells and SLE disease activity index  (SLEDAI) (n = 54) Figure 4
(A) Negative correlation between 
CD4+CD25+CD45RO+ T cell frequency and anti-DNA 
antibody titers in our population sample and correla-
tions between CD4+CD25+CD45RO+ T cell frequency 
and anti-DNA antibody titers in patients relatives 
and controls (B) Negative correlation between the 
percentage of CD25+CD45RO+ in total CD4+ PBMC 
cells and SLE disease activity index (SLEDAI) (n = 
54).BMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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index ( = -0.502, P = 0.002) (Figure 4B). However, no
correlation was found with the SLICC damage index ( =
0.071,  P  = 0.658). There was no significant difference
between the frequency of CD4+CD25+CD45RO+ T cells in
patients untreated or treated with corticosteroids
(Kruskall-Wallis Test: z = 0.07, P  = 0.94), antimalarial
agents (Kruskall-Wallis Test: z = 1.41, P = 0.158), or both
drugs (Kruskall-Wallis Test: z = -1.32, P = 0.132). Note-
worthy, no correlation was found between total lym-
phocyte counts and the frequency of
CD4+CD25+CD45RO+  T cell ( = 0.021, P  = 0.758),
excluding the possibility that lymphopenia led to this
phenotype. There was also no correlation with age ( =
0.153, P = 0.100).
Variation of CD4+CD25+CD45RO+ T cell frequency with 
the development and remission of SLE-related symptoms
In two SLE patients variations in CD4+CD25+CD45RO+ T
cell frequency as a function of disease onset and progres-
sion and with treatment were evaluated. A 33-year-old
Caucasian woman was initially enrolled in this study as a
healthy relative of an SLE patient. At the time of recruit-
ment, the frequency of CD4+CD25+CD45RO+ T cells in
this subject was 4.60% (Figure 5A). One year later, this
woman presented classical SLE clinical symptoms, lym-
phopenia, positive anti-dsDNA antibody, positive lupic
anticoagulant and a SLEDAI of 10. Upon establishment of
the diagnosis of SLE, a new measurement of Treg fre-
quency showed a decrease to 2.88% (Figure 5B), suggest-
ing the involvement of CD4+CD25+CD45RO+  T cell
frequency in the onset of symptoms. In a second case a 67-
year-old female SLE patient, diagnosed three years before,
developed an SLE flare with symptoms of acute isquemic
stroke, hemolytic anemia, impaired renal function, anti-
nuclear, anti-dsDNA and anticardiolipin antibodies and
hipocomplementemia. The SLEDAI score was 42. A regi-
men of low-dose corticosteroids and antimalarials had
previously provided a good control of disease. At this
point the CD4+CD25+CD45RO+  T cell frequency was
4.22% (Figure 5C). After anticoagulant and intravenous
corticosteroid therapies, the CD4+CD25+CD45RO+ T cell
frequency was 4.30% (Figure 5D). In addition to antico-
agulants and intravenous corticosteroids therapies, IVIg
therapy administration was deemed necessary. Upon IVIg
treatment, the patient's CD4+CD25+CD45RO+ T cell fre-
quency increased to 7.12% (Figure 5E) and she showed
progressive clinical and laboratorial improvement, and
the SLEDAI score decreased to 12 after three weeks of
treatment. Taken together these results support the idea
that decreased CD25+ T cell frequency is associated with
disease activity.
Peripheral CD4+CD25+CD45RO+ T cell frequency is highly 
heritable
Relatives of SLE patients presented intermediate
CD4+CD25+CD45RO+ T cell frequencies between patients
and controls (Figure 1B), suggesting that Treg frequency
might represent a genetic trait. Any potential bias due to
recruitment design was excluded based on the following
observations: for each family all samples were collected
and processed on the same day; there were no significant
differences in Treg frequency between families collected in
different days. Treg frequencies in genetically unrelated
family members and in controls collected and processed
on the same day are within the range of healthy controls
analyzed during the whole period of the study.
A high CD4+CD25+CD45RO+ T cell frequency heritability,
defined as the proportion of variation of this trait attribut-
able to genetic factors, was estimated at 0.85 ± 0.09 (P =
1.05e-10) (Additional file 2). As for most complex traits,
there was no clear segregation pattern of
CD4+CD25+CD45RO+ T cell frequency with affection sta-
tus in the families. However, because relatives often
CD4+CD25+CD45RO+ T cell frequency of an SLE patient  before (A) and after (B) SLE diagnosis Figure 5
CD4+CD25+CD45RO+ T cell frequency of an SLE 
patient before (A) and after (B) SLE diagnosis. (C) 
CD4+CD25+CD45RO+ T cell frequency of an SLE patient at 
the time of flare, (D) upon corticosteroid and anticoagulant 
therapy and (E) after IVIg administration. Lymphocytes gated 
according to forward and side scatter (FSC/SSC) from PBMC 
were screened by flow cytometry for the presence of 
CD4+CD25+CD45RO+ T cells. The FACS panel representing 
CD4+CD25+CD45RO+ is gated on CD4+ cells.
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present SLE-related autoimmunity symptoms even when
not meeting the full diagnostic criteria, we tested the asso-
ciation of CD4+CD25+CD45RO+ T cell frequency with the
severity of these suboptimal autoimmune symptoms
through a 10-item survey questionnaire administered to
patients and relatives (Table 1). The number of positive
answers was inversely correlated with the frequency of
CD4+CD25+CD45RO+ T cells (Kruskall-Wallis test: H =
20.7, P = 0.014) (Figure 6), as expected if the extent of
clinical manifestations is associated with the frequency of
CD4+CD25+CD45RO+ T cells. The results therefore pro-
vide evidence that CD4+CD25+CD45RO+  T cells fre-
quency constitutes a genetic trait associated with SLE
manifestations, which can be used for genetic mapping.
Lower frequency of CD4+CD25+CD45RO+ T cells is 
associated with specific CTLA4 and TGF gene variants
The evidence for familiar transmission prompted us to
test putative functional polymorphisms in the candidate
genes CTLA4, TGF, FOXP3, IL2 and CD25 for association
with CD4+CD25+CD45RO+ T cell frequency. All geno-
typic distributions were in HWE and all the polymorphic
markers within the same gene were in LD. A significant
association of the CTLA4  3'UTR microssatelite marker
with CD4+CD25+CD45RO+ T cell frequency was found
(Kruskal-Wallis test: H = 40.57, P = 0.009), with geno-
types 104/104 and 106/106 associated with lower
(2.64%) and higher (5.47%) frequency of
CD4+CD25+CD45RO+ T cells, respectively (Table 2). This
result is particularly relevant because, in our sample, allele
104 has previously been found to increase susceptibility
to disease, while allele 106 showed a protective effect [27].
The TGF rs180047 SNP was also significantly associated
with the frequency of CD4+CD25+CD45RO+  T cells
(Kruskal-Wallis test: H = 8.099, P = 0.004). Heterozygosis
was associated with lower frequencies of
CD4+CD25+CD45RO+ T cells (Table 2). Because the C
allele has very low frequency in the general population
(6%), there were no homozygous individuals for this
allele in our sample.
Both the FOXP3  rs12843496 SNP and the intron 0
marker, located in the promoter/enhancer region of the
gene, were nominally associated with SLE (2 = 6.14, P =
0.013 and 2 = 10.30, P = 0.036, respectively) (Table 3).
The A allele of rs12843496 was more frequent in patients
than in controls. The susceptibility allele 4 of the intron 0
microsatellite marker was more frequent in patients (2 =
6.63, P=0.01) and a protective allele 6 more frequent in
controls (2 = 4.03, P = 0.04) (Table 3). No association
was found with CD4+CD25+CD45RO+ T cell frequency
(Table 2). There was no evidence for association of any
other tested gene marker with CD4+CD25+CD45RO+ T
cell frequency or with SLE (data not shown).
Taken together these results indicate that CTLA4  and
TGF  gene variants contribute to the determination of
CD4+CD25+CD45RO+ T cell frequency in PBMC, inde-
pendently of disease activity, while the involvement of
FOXP3  gene variants in SLE is likely not mediated by
CD4+CD25+CD45RO+ T cell frequency.
No correlation was found between CTLA-4, TGF-, IL-2 or
CD25 expression levels and the frequency of
CD4+CD25+CD45RO+ T cells, disease status or marker
genotypes (data not shown). There was a trend towards
higher levels of FOXP3 mRNA in SLE patients, although
not significant (Mann-Whitney U-test: z = -1.78, P  =
0.075), and in individuals carrying the A allele of FOXP3
rs12843496 (Mann-Whitney U-test: z = 4.95, P = 0.026).
These results suggest that variability in
CD4+CD25+CD45RO+ T cell frequency associated with
SLE is not influenced by altered expression of any of the
tested genes.
Discussion
The present study supports and expands previous observa-
tions of decreased CD4+CD25+CD45RO+ T cell frequency
in SLE patients. It further demonstrates a clear gender dif-
ference in the distribution of this regulatory T cell subset
and provides evidence suggesting that
CD4+CD25+CD45RO+  T cell frequency variation may
result from a defect in the conversion of FOXP3+CD25-
into FOXP3+CD25+cells. CD4+CD25+CD45RO+ T cell fre-
Relative distribution of CD4+CD25+CD45RO+ T cell fre- quency in patients and their relatives (n = 231) with the  number of positive answers to the survey questionnaire, indi- cating a negative correlation between the frequency of  CD4+CD25+CD45RO+ T cells and the number of positive  answers to the survey questionnaire Figure 6
Relative distribution of CD4+CD25+CD45RO+ T cell 
frequency in patients and their relatives (n = 231) 
with the number of positive answers to the survey 
questionnaire, indicating a negative correlation 
between the frequency of CD4+CD25+CD45RO+ T 
cells and the number of positive answers to the sur-
vey questionnaire.
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Table 2: Distribution of Treg frequency according to genotypes of the CTLA4, TGF FOXP3, IL2 and CD25 genes (non-parametric 
analysis of variance – Kruskall-Wallis test). 
CTLA4 rs 231775 genotypes N (%) Median % CD4+CD25+CD45RO+Cells Kruskall-Wallis Test P
A/A 39(13.22) 3.30
A/G 115(38.98) 2.98 1.24 0.537
G/G 141 (47.80) 2.80
CTLA4 3'UTR microssatelite genotypes
88/88 100 (38.02) 3.10
88/104 9 (3.42) 2.66
88/106 26 (10.27) 2.58 40.57 0.0009
104/104 3 (1.14) 2.54
106/106 5 (1.90) 4.01
Rare 119 (45.25) 2.81
TGF rs18000469 genotypes
C/C 37(12.38) 3.55
C/T 122 (40.80) 2.94 0.427 0.808
T/T 140 (46.82) 3.27
TGF rs18000471 genotypes
G/G 255 (86.44) 3.29 8.10 0.004
G/C 41 (13.56) 2.10
FOXP3 FOX0 microssatelite genotypes
1/4 3 (1.42) 2.54
1/5 2 (0.95) 2.65
4/4 68 (32.23) 3.15
4/5 76 (36.02) 2.77
4/6 21 (9.96) 2.58 9.06 0.911
4/7 3 (1.42) 5.22
5/5 26 (12.32) 2.59
5/6 6 (2.84) 2.08
Rare 6 (2.84) 3.22
FOXP3 FOX5 microssatelite genotypes
1/3 3 (1.59) 2.87
1/4 4 (2.10) 3.79
3/3 77 (40.74) 3.10
3/8 5 (2.65) 2.54
3/10 10 (5.29) 3.17
3/12 13 (6.88) 2.99
3/13 11 (5.82) 2.36
3/14 43 (22.75) 2.51 9.06 0.911
3/15 3 (1.59) 3.16
3/16 8 (4.23) 3.54
3/18 3 (1.59) 2.74
3/19 2 (1.06) 3.50
7/13 2 (1.06) 3.76
8/14 2 (1.06) 2.00
Rare 3 (1.59) 3.19
IL2 rs20699762 genotypes
G/G 137 (47.90) 3.55BMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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quency is shown to be negatively correlated with disease
activity and with anti-dsDNA antibodies in the patient
and control groups, and to change with development and
remission of SLE symptoms in two documented cases. The
study also established that the frequency of
CD4+CD25+CD45RO+ T cells is highly heritable in fami-
lies affected with SLE, that it is negatively correlated with
the severity of SLE-associated manifestations in patients
and relatives, and that it is influenced by genetic variants
in the CTLA4 and TGF genes.
We initially analyzed the frequency of Treg with the avail-
able anti-CD25 an CD45RO antibodies as described by
Jonuleit et al. [35], who have demonstrated that human
CD4+CD25+CD45RO+ T cells are highly enriched in T
cells with suppressor properties. CD25 and CD45RO are
also markers of activation and one could argue that our
measurement concerned conventional activated cells. Sev-
eral observations indicate that this is not the case. First,
the total frequency of CD45RO+ cells was not significantly
different between patients' and controls' PBMC, indicat-
ing that conventional activated cells are not enriched in
SLE patients' PMBC. Second, once a FOXP3 antibody
became available, we have tested this marker in a subset
of patients. All together our analyses reveal that, when
compared to controls, patients had a significantly
decreased frequency of CD25+ cells of either the CD4+
CD45RO+  or the FOXP3+  phenotype, supporting the
notion that the CD4+CD25+CD45RO+ T cell subset is
enriched in Treg. Hence, the analyses we presented here
most likely concern bona fide Treg. Furthermore, while the
CD4+FOXP3+  cell subset was comparable between
patients and controls, patients had a significantly higher
frequency of FOXP3+ CD25- cells, suggesting that they are
unable to convert FOXP3+ CD25- into FOXP3+ CD25+
cells. Previous observations endorse this hypothesis: SLE
patients display multiple signaling defects leading to a
defective IL-2 production [37], and CD4+FOXP3+ thymo-
cytes from IL-2-/- mice have very few cells expressing CD25
when compared to wild type mice [38]. In fact, IL-2 does
G/T 121 (42.31) 3.81 1.906 0.386
T/T 28 (9.79) 3.33
IL2 rs3087209 genotypes
G/G 28 (9.82) 3.04
G/T 101 (35.44) 3.81 0.944 0.624
T/T 156 (54.74) 3.16
CD25D10S189 genotypes
1/1 7 (2.54) 2.58
1/2 57 (20.73) 3.08
1/3 1 (0.36) 4.06
1/4 28 (10.18) 2.92
1/5 21 (7.64) 3.37
2/2 35 (12.73) 3.65 14.932 0.312
2/4 62 (22.54) 3.51
2/5 32 (11.64) 3.25
3/4 3 (1.09) 2.51
4/4 11 (4.00) 2.68
4/5 16 (5.82) 2.55
5/5 2 (0.73) 5.77
CD25rs2274037 genotypes
A/A 140 (83.83) 4.29 0.008 0.931
A/G 27 (16.17) 4.23
CD25rs1570538 genotypes
C/C 50 (25.25) 4.43
C/T 110 (55.56) 3.67 2.110 0.348
T/T 38 (19.19) 3.51
N represents the number of individuals.
Table 2: Distribution of Treg frequency according to genotypes of the CTLA4, TGF FOXP3, IL2 and CD25 genes (non-parametric 
analysis of variance – Kruskall-Wallis test).  (Continued)BMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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Table 3: Genetic association between FOXP3 markers and SLE.
Patients Controls
rs 12843496 allele Number of alleles (%) Number of alleles (%) 2 P OR (95%CI)
G 293 (96.7) 233 (100) -
A 10 (3.3) 0 (0.0) 6.137 0.013 -
Total 303 (100) 233 (100)
FOX0 allele
1 7 (2.3) 4 (1.7) 0.04 0.84 1.38 (0.40–4.78)
4 189 (61.6) 121 (50.2) 6.63 0.01 1.59 (1.13–2.24)
5 97 (31.6) 93 (38.6) 2.61 0.10 0.74 (0.52–1.05)
6 11 (3.6) 19 (7.9) 4.03 0.04 0.24 (0.11–0.52)
Rare 3 (0.9) 4 (1.6) 0.10 0.75 0.81 (0.18–3.63)
Total 307 (100) 241 (100) 10.3 0.036
FOX5 allele
3 188 (63.7) 137 (57.9) 1.65 0.20 1.28 (0.90–1.82)
8 6 (2.0) 6 (2.6) 0.01 0.92 0.80 (0.25–2.49)
10 13 (4.4) 4 (1.7) 2.27 0.13 2.66 (0.86–8.28)
12 17 (5.8) 21 (8.9) 1.53 0.22 0.99 (0.54–1.80)
13 7 (2.4) 7 (3.0) 0.03 0.87 0.79 (0.27–2.29)
14 46 (15.6) 38 (16.2) <0.01 0.95 0.96 (0.60–1.53)
15 3 (1.0) 5 (2.1) 0.43 0.51 0.47 (0.11–2.00)
16 7 (2.4) 9 (3.8) 0.52 0.47 0.61 (0.22–1.66)
18 0 (0.0) 5 (2.1) 4.26 0.04 -
Rare 8 (2.7) 4 (1.7) 0.23 0.63 1.61 (0.48–5.41)
Total 295 (100) 235 (100) 14.77 0.10
rs 12843496 genotypes
GG 136 (93.8) 77 (100) 3.51 0.06 -
GA 8 (5.5) 0 (0.0) 2.96 0.09 -
AA 1 (0.7) 0 (0.0) 0.11 0.74 -
Total 145 (100) 77 (100) 4.98 0.08
FOX0 genotypes
4/4 50 (33.8) 22 (25.3) 1.48 0.22 1.50 (0.83–2.72)
4/5 63 (42.6) 35 (40.2) 0.05 0.83 1.10 (0.64–1.88)
4/6 9 (6.1) 6 (6.9) <0.01 0.98 0.87 (0.30–2.55)
5/5 12 (8.1) 13 (14.9) 2.02 0.16 0.50 (0.21–1.16)
Rare 14 (9.4) 11 (12.7) 0.30 0.50 0.72 (0.31–1.67)
Total 148 (100) 87 (100) 4.35 0.36
FOX5 genotypes
3/3 59 (33.8) 28 (33.3) 0.72 0.40 1.33 (0.76–2.32)
3/12 8 (5.4) 5 (6.0) 0.02 0.90 0.90 (0.29–2.85)
3/13 6 (4.1) 4 (4.8) 0.01 0.94 0.85 (0.23–3.08)
3/14 32 (21.6) 16 (19.1) 0.09 0.77 1.17 (0.60–2.29)
3/15 2 (1.4) 3 (3.6) 0.38 0.54 0.38 (0.06–2.32)
3/16 5 (3.4) 3 (3.6) 0.09 0.77 0.94 (0.22–4.05)
3/18 0 (0.0) 5 (6.0) 6.4 0.01 -
14/14 4 (2.7) 3 (3.6) <0.01 0.98 0.75 (0.16–3.43)
Rare 32 (21.6) 17 (20.2) 0.01 0.94 1.09 (0.56–2.10)
Total 148 (100) 84 (100) 11.1 0.10
Allele and genotype frequencies, 2 test and Odds Ratio for the FOXP3 rs12843496, intron 0 and intron 5 microssatelites in SLE patients and healthy 
individuals.BMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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not seem to be required for the induction of FOXP3
expression but is required for the survival and expansion
of Treg cells in the periphery, leading to autoimmune
manifestations.
The percentage of CD45RO-CD31+ RTE was not correlated
with disease or with CD4+CD25+CD45RO+ T cell fre-
quency, ruling out a defect in thymic export. The faster
decrease rate of CD4+CD25+ CD31+ cells in SLE patients,
however, is indicative of a specific thymic defect leading
to a decreased Treg production and thus contributing to
the lower frequency of these cells in the periphery. The
observed decrease of CD4+CD25+CD45RO+  T cell fre-
quency in patients might also result from cell migration to
the sites of inflammation. However, this hypothesis seems
unlikely because patients with rheumatoid arthritis dis-
play enriched CD4+CD25+CD45RO+ T cells not only in
inflamed joints but also in peripheral blood [39].
The difference found in CD4+CD25+CD45RO+ T cell fre-
quency between males and females is remarkable, given
the much higher prevalence of SLE in females. This differ-
ence is very significant in the control population, suggest-
ing this may be a gender specific trait that renders females
more susceptible to SLE. The lack of significance in the
patient group may be due to the very small number of
males, while in the relatives' group this might be
explained by the high heterogeneity of this population,
where only some individuals carry the disease susceptibil-
ity factors.
The significant negative correlation of
CD4+CD25+CD45RO+ T cell frequency with anti-dsDNA
antibodies observed in the patients and in the relatives
suggests that these cells may be able to inhibit antinuclear
antibody production by B cells, and therefore an addi-
tional mechanism through which loss of immunological
tolerance may be achieved in SLE. This phenomenon may
also occur in the relatives, but the fact that they display a
positive correlation between CD4+CD25+CD45RO+ T cell
frequency and anti-dsDNA antibodies may represent a
compensation effect in which the relatives' are able to
overcome this pathogenic mechanism.
CD4+CD25+CD45RO+ T cell frequency was also associ-
ated with disease activity and with the extent of clinical
manifestations. This suggests a direct involvement in dis-
ease development and prognosis, which is corroborated
by the variation observed with onset and remission of
symptoms in the two documented cases. The frequency of
CD4+CD25+CD45RO+ T cells was not associated with the
use of immunosuppressive drugs. Whether these therapies
affect basal frequencies of Treg was not addressed in the
present work as it would require longitudinal studies.
Interestingly, in one case the clinical improvement that
followed IVIg administration was associated with
increased CD4+CD25+CD45RO+ T cell frequency, suggest-
ing that this treatment may influence Treg generation or
maintenance [40].
The CD4+CD25+CD45RO+ T cell frequency was highly
heritable in the affected families and was also strongly
correlated with the extent of autoimmune manifestations
in patients and in affected and unaffected relatives, in con-
cordance with the clustering of autoimmune diseases and/
or autoimmune-related phenotypes observed in these
families. These findings are of particular importance
because they show a contribution of genetic factors to the
decrease in CD4+CD25+CD45RO+ T cell frequency and
thus substantiate a genetic basis for SLE. Although we still
cannot establish whether the decrease in
CD4+CD25+CD45RO+ T cells is a cause or a consequence
of autoimmune manifestations in SLE, we show evidence
for the existence of genetic factors that, by influencing this
trait, may contribute to SLE.
The frequency of CD4+CD25+CD45RO+  T cells likely
results from a combination of processes regulating their
expansion and survival in the periphery, and therefore
multiple genetic factors may contribute to this trait. This
study provided evidence for an involvement of the CTLA4
and TGF genes. The specific polymorphisms associated
with CD4+CD25+CD45RO+ cell frequency were not corre-
lated with CTLA-4 and TGF- mRNA expression level var-
iation; expression levels in turn were not associated with
cell variation or with disease status, indicating that a func-
tional defect in these genes, rather than changes in expres-
sion levels, contributes to the observed
CD4+CD25+CD45RO+ T cell phenotype in SLE patients.
In mouse models the generation and expansion of Treg
are dependent on CTLA-4 and TGF- respectively, [41-46].
CTLA-4-/- animals have reduced numbers of CD4+CD25+ T
cells with reduced regulatory capacity, while TGF- regu-
lates the Treg cell pool size and expression of the Treg
commitment factor Foxp3 [11]. TGF has also been
shown to induce CD4+CD25+ regulatory T cells in vitro,
which were able to prevent a murine lupus-like syndrome
and graft versus host disease [47]. In humans, it was dem-
onstrated that it has the capacity to expand CD4+CD25+ in
normal subjects [48]. Our results therefore extend the role
of these genes in the regulation of Treg frequency and
autoimmunity to humans.
Other Treg specific candidate genes that may contribute to
the determination of the size of the Treg pool are the
FOXP3 commitment factor and the IL2 and CD25 genes,
which deliver crucial growth and/or survival signals to
these cells. In the study population, a promoter polymor-
phism (rs12843496) in the FOXP3 gene was associatedBMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
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with SLE but not with the frequency of
CD4+CD25+CD45RO+ T cells, indicating that susceptibil-
ity to the disease is mediated by mechanisms other than
influencing Treg frequency. The rs12843496 allele A asso-
ciated with SLE creates a putative binding site to the tran-
scriptional activator PLAG1 in the FOXP3 promoter
region, which may explain the slightly higher FOXP3
mRNA expression found in SLE patients. A compensatory
mechanism can be hypothesized to account for the main-
tenance of a normal mean CD4+FOXP3+ cell frequency in
patients even in the presence of increased frequency of
this allele, and is plausible since FOXP3 can be upregu-
lated by other cytokines.
The  IL2  and  CD25  genes were not associated with
CD4+CD25+CD45RO+ T cell frequency or with SLE. It
should be remarked that the study population sample is
small and that we focused on genotyping known func-
tional polymorphisms because of their previously
reported relevance, but did not fully cover genetic varia-
tion in any of these genes. Our genetic results should
therefore be considered preliminary.
Conclusion
In conclusion, we report that low peripheral
CD4+CD25+CD45RO+ T cell frequency is a genetically
determined predisposing factor for SLE development. Our
results demonstrate the contribution of specific genes and
suggest pathways involved in the establishment of
CD4+CD25+CD45RO+ T cell frequency. Whether a defect
in number or function is a prerequisite for SLE develop-
ment remains to be understood. Most importantly, our
findings open new perspectives for therapy for SLE
patients based on the manipulation of Treg. Criteria for
the selection of candidate patients for Treg based therapy
remains to be fully established but likely should include
evaluation of Treg frequency and analysis of genes
involved in Treg generation or maintenance, strongly ben-
efiting the management of this autoimmune disease.
Authors' contributions
MB planed and conducted experiments, prepared the
database, performed the statistical analyses and wrote the
manuscript; RCF and LL conducted experiments; MFF and
CC conducted experiments and performed clinical evalu-
ation of patients and their relatives; ES and MA collected
samples, performed clinical evaluation of patients and
their relatives and prepared the database; BM, RA, and CV
selected families for the study and supervised the blood
collection; CF participated in the experimental design,
selected families for the study, performed clinical evalua-
tion of patients and their relatives and discussed the
results; JFV participated in the autoantibody experiments;
LMV collected samples and revised the manuscript; JD
participated in the experimental design, discussed the
results and wrote the manuscript; AV supervised the over-
all project, participated in the experimental design, dis-
cussed the results and wrote the manuscript. All authors
read and approved the final manuscript.
Additional material
Acknowledgements
The authors would like to thank Isabel Reis, Ana Tam, Maria João Antunes, 
the Associação dos Doentes com Lupus, and also Leonor Miranda, for their 
precious help in the recruitment of patients and collection of blood sam-
ples. We also thank the Serviço de Imunohemoterapia, Hospital Egas 
Moniz, as well as all the blood donors for their participation in this study. 
The authors thank Sofia Marques for her help in the mRNA experiments, 
Isabel Marques for her bioinformatics support and António Coutinho for 
advice and critical reading of the manuscript. M. Barreto was supported by 
Fundação para a Ciência e Tecnologia.
References
1. Rocha B, von Boehmer H: Peripheral selection of the T cell rep-
ertoire.  Science 1991, 251:1225-8.
2. Van Parijs L, Abbas AK: Homeostasis and self-tolerance in the
immune system: turning lymphocytes off.  Science 1998,
280:243-8.
3. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F,
Sakaguchi S: Thymus and autoimmunity: production of
CD25+CD4+ naturally anergic and suppressive T cells as a
key function of the thymus in maintaining immunologic self-
tolerance.  J Immunol 1999, 162:5317-26.
4. Sakaguchi S: Naturally Arising CD4+ Regulatory T Cells for
Immunologic Self-Tolerance and Negative Control of
Immune Responses.  Annu Rev Immunol 2004, 22:531-562.
5. Hsu WT, Suen JL, Chiang BL: The role of CD4CD25 T cells in
autoantibody production in murine lupus.  Clin Exp Immunol
2006, 145:513-9.
6. Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM: Major his-
tocompatibility complex class II-positive cortical epithelium
mediates the selection of CD4(+)25(+) immunoregulatory T
cells.  J Exp Med 2001, 194:427-38.
7. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee
KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative
disorders with early lethality in mice deficient in Ctla-4.  Sci-
ence 1995, 270:985-8.
8. Kwon H, Jun HS, Khil LY, Yoon JW: Role of ctla-4 in the activa-
tion of single- and double-positive thymocytes.  J Immunol
2004, 173:6645-53.
9. Boden E, Tang Q, Bour-Jordan H, Bluestone JA: The role of CD28
and CTLA4 in the function and homeostasis of CD4+CD25+
regulatory T cells.  Novartis Found Symp 2003, 252:55-63.
Additional file 1
Total sample characteristics and samples used in each of the analyses.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-10-5-S1.doc]
Additional file 2
Heritability test for CD4+CD25+CD45RO+ regulatory T cell frequency 
in SLE families.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-10-5-S2.doc]BMC Immunology 2009, 10:5 http://www.biomedcentral.com/1471-2172/10/5
Page 14 of 14
(page number not for citation purposes)
10. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen
R, Sidman C, Proetzel G, Calvin D, et al.: Targeted disruption of
the mouse transforming growth factor-beta 1 gene results in
multifocal inflammatory disease.  Nature 1992, 359:693-9.
11. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA: TGF-beta regu-
lates in vivo expansion of Foxp3-expressing CD4+CD25+
regulatory T cells responsible for protection against diabe-
tes.  Proc Natl Acad Sci USA 2004, 101:4572-7.
12. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G: Ex vivo
isolation and characterization of CD4(+)CD25(+) T cells
with regulatory properties from human blood.  J Exp Med
2001, 193:1303-10.
13. Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regula-
tory T cells in patients with systemic lupus erythematosus.  J
Autoimmun 2003, 21:273-6.
14. Valencia X, Yarboro C, Illei G, Lipsky PE: Deficient
CD4+CD25high T regulatory cell function in patients with
active systemic lupus erythematosus.  J Immunol 2007,
178:2579-88.
15. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz
M, Exley M, Wilson B, et al.: Multiple immuno-regulatory defects
in type-1 diabetes.  J Clin Invest 2002, 109:131-40.
16. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of func-
tional suppression by CD4+CD25+ regulatory T cells in
patients with multiple sclerosis.  J Exp Med 2004, 199:971-9.
17. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell
development by the transcription factor Foxp3.  Science 2003,
299:1057-61.
18. Wildin RS, Smyk-Pearson S, Filipovich AH: Clinical and molecular
features of the immunodysregulation, polyendocrinopathy,
enteropathy, X linked (IPEX) syndrome.  J Med Genet 2002,
39:537-45.
19. Gavin M, Rudensky A: Control of immune homeostasis by nat-
urally arising regulatory CD4+ T cells.  Curr Opin Immunol 2003,
15:690-6.
20. Kotzin BL: Systemic lupus erythematosus.  Cell 1996, 85:303-6.
21. Via CS, Handwerger BS: B-cell and T-cell function in systemic
lupus erythematosus.  Curr Opin Rheumatol 1993, 5:570-4.
22. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA: Cytokines and
systemic lupus erythematosus.  Ann Rheum Dis 2000, 59:243-51.
23. Hochberg MC: Updating the American College of Rheumatol-
ogy revised criteria for the classification of systemic lupus
erythematosus.  Arthritis Rheum 1997, 40:1725.
24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH:
Derivation of the SLEDAI. A disease activity index for lupus
patients. The Committee on Prognosis Studies in SLE.  Arthri-
tis Rheum 1992, 35:630-40.
25. Johnson AE, Gordon C, Hobbs FD, Bacon PA: Undiagnosed sys-
temic lupus erythematosus in the community.  Lancet 1996,
347:367-9.
26. Ferreira R, Barreto M, Santos E, Pereira C, Martins B, Andreia R, Cre-
spo F, Viana JF, Vasconcelos C, Ferreira C, et al.: Heritable factors
shape natural human IgM reactivity to Ro60/SS-A and may
predispose for SLE-asssociated IgG anti-Ro and anti-La
autoantibody production.  J Autoimmun 2005, 25:155-163.
27. Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, Mar-
tins B, Andreia R, Viana JF, Crespo F, et al.: Evidence for CTLA4 as
a susceptibility gene for systemic lupus erythematosus.  Eur J
Hum Genet 2004, 12:620-6.
28. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe
JC, Carter ND, Spector TD: Genetic control of the circulating
concentration of transforming growth factor type beta1.
Hum Mol Genet 1999, 8:93-7.
29. Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM,
Weiskirchen R: Analysis of the transforming growth factor-
beta1 (TGF-beta1) codon 25 gene polymorphism by Light-
Cycler-analysis in patients with chronic hepatitis C infection.
Cytokine 2003, 24:173-81.
30. Bassuny WM, Ihara K, Sasaki Y, Kuromaru R, Kohno H, Matsuura N,
Hara T: A functional polymorphism in the promoter/
enhancer region of the FOXP3/Scurfin gene associated with
type 1 diabetes.  Immunogenetics 2003, 55:149-56.
31. Fedetz M, Matesanz F, Caliz R, Ferrer MA, Collado MD, Alcina A,
Martin J: Lack of association between -384 and 114 IL-2 gene
polymorphisms and rheumatoid arthritis.  J Rheumatol 2003,
30:435-7.
32. Matesanz F, Caro-Maldonado A, Fedetz M, Fernandez O, Milne RL,
Guerrero M, Delgado C, Alcina A: IL2RA/CD25 polymorphisms
contribute to multiple sclerosis susceptibility.  J Neurol 2007,
254:682-4.
33. Almasy L, Blangero J: Multipoint quantitative-trait linkage anal-
ysis in general pedigrees.  Am J Hum Genet 1998, 62:1198-211.
34. Abecasis GR, Cookson WO: GOLD – graphical overview of link-
age disequilibrium.  Bioinformatics 2000, 16:182-3.
35. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH:
Identification and functional characterization of human
CD4(+)CD25(+) T cells with regulatory properties isolated
from peripheral blood.  J Exp Med 2001, 193:1285-94.
36. Kimmig S, Przybylski GK, Schmidt CA, Laurisch K, Mowes B, Rad-
bruch A, Thiel A: Two subsets of naive T helper cells with dis-
tinct T cell receptor excision circle content in human adult
peripheral blood.  J Exp Med 2002, 195:789-94.
37. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC: Altered signal
transduction in SLE T cells.  Rheumatology (Oxford) 2007,
46:1525-30.
38. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for
interleukin 2 in Foxp3-expressing regulatory T cells.  Nat
Immunol 2005, 6:1142-51.
39. Cao D, Vollenhoven Rv R, Klareskog L, Trollmo C, Malmstrom V:
CD25brightCD4+ regulatory T cells are enriched in inflamed
joints of patients with chronic rheumatic disease.  Arthritis Res
Ther 2004, 6:R335-46.
40. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Del-
ignat S, Elluru S, Bayry J, Lacroix-Desmazes S, et al.: Expansion of
CD4+CD25+ regulatory T cells by intravenous immunoglob-
ulin: a critical factor in controlling experimental autoim-
mune encephalomyelitis.  Blood 2008, 111:715-22.
41. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associ-
ated antigen 4 plays an essential role in the function of
CD25(+)CD4(+) regulatory cells that control intestinal
inflammation.  J Exp Med 2000, 192:295-302.
42. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N,
Mak TW, Sakaguchi S: Immunologic self-tolerance maintained
by CD25(+)CD4(+) regulatory T cells constitutively express-
ing cytotoxic T lymphocyte-associated antigen 4.  J Exp Med
2000, 192:303-10.
43. Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, San-
som DM: Inhibition of human T cell proliferation by CTLA-4
utilizes CD80 and requires CD25+ regulatory T cells.  Eur J
Immunol 2002, 32:2888-96.
44. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V,
Romagnani P, Maggi E, Romagnani S: Phenotype, localization, and
mechanism of suppression of CD4(+)CD25(+) human thy-
mocytes.  J Exp Med 2002, 196:379-87.
45. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA:
Distinct roles of CTLA-4 and TGF-beta in CD4(+)CD25(+)
regulatory T cell function.  Eur J Immunol 2004.
46. Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, Prot-
schka M, Galle PR, Neurath MF, Blessing M: Cutting edge: TGF-
beta signaling is required for the in vivo expansion and
immunosuppressive capacity of regulatory CD4+CD25+ T
cells.  J Immunol 2004, 173:6526-31.
47. Su H, Ye DQ, Wang BL, Fang XH, Chen J, Wang Q, Li WX, Zhang N:
Transforming growth factor-beta1-induced CD4+CD25+
regulatory T cells in vitro reverse and prevent a murine
lupus-like syndrome of chronic graft-versus-host disease.  Br
J Dermatol 2008, 158:1197-209.
48. Lu LY, Chu JJ, Lu PJ, Sung PK, Hsu CM, Tseng JC: Expression of
intracellular transforming growth factor-beta1 in
CD4(+)CD25(+) cells in patients with systemic lupus ery-
thematosus.  J Microbiol Immunol Infect 2008, 41:165-73.